Dextrose monohydrate injection (10%)

Jump to navigation Jump to search
Dextrose monohydrate injection (10%)
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Adeel Jamil, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Dextrose monohydrate injection (10%) is a sterile intravenous solution that is FDA approved for the treatment of and indicated for admixture with amino acids or dilution with other compatible IV fluids to provide a 5% final dextrose concentration for intravenous infusion in patients whose condition requires parenteral nutrition. Common adverse reactions include hyperosmolar syndrome, febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

  • 10% Dextrose Injection, USP (concentrated dextrose in water) in a partial-fill container is indicated for admixture with amino acids or dilution with other compatible IV fluids to provide a 5% final dextrose concentration for intravenous infusion in patients whose condition requires parenteral nutrition.

Dosing Information

  • Concentrated Dextrose in Water is administered by slow intravenous infusion (a) after admixture with amino acid solutions or (b) after dilution with other compatible IV fluids. Dosage should be adjusted to meet the requirements of each individual patient.
  • The maximum rate at which dextrose can be infused without producing glycosuria is 0.5 g/kg of body weight /hr. About 95% of the dextrose is retained when infused at a rate of 0.8 g/kg/hr.
  • Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.
  • A list of nutritional admixture values is appended.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Drug Interaction
  • Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.
  • Some opacity of the plastic due to moisture absorption during sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.
  • WARNING: Do not use flexible container in series connections.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Dextrose monohydrate injection (10%) in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Dextrose monohydrate injection (10%) in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Dextrose monohydrate injection (10%) FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Dextrose monohydrate injection (10%) in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Dextrose monohydrate injection (10%) in pediatric patients.

Contraindications

  • A concentrated dextrose solution should not be used when intracranial or intraspinal hemorrhage is present nor in the presence of delirium tremens if the patient is already dehydrated.
  • Dextrose Injection, USP without electrolytes should not be administered simultaneously with blood through the same infusion set because of the possibility that pseudoagglutination of red cells may occur.

Warnings

  • Concentrated dextrose in water should be administered only after suitable dilution. Hypertonic dextrose solutions should be given slowly. Significant hyperglycemia and possible hyperosmolar syndrome may result from too rapid administration. The physician should be aware of the symptoms of hyperosmolar syndrome, such as mental confusion and loss of consciousness, especially in patients with chronic uremia and those with known carbohydrate intolerance.
  • The intravenous administration of this solution can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.
  • WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
  • Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
FOR PERIPHERAL VEIN ADMINISTRATION
  • Hypertonic dextrose solutions (above 5% concentration) should be given slowly, preferably through a small bore needle into a large vein, to minimize venous irritation.
FOR CENTRAL VENOUS ADMINISTRATION
  • Concentrated dextrose should be administered via central vein after appropriate admixture or dilution when required.

PRECAUTIONS

  • Electrolyte deficits, particularly in serum potassium and phosphate, may occur during prolonged use of concentrated dextrose solutions. Blood electrolyte monitoring is essential, and fluid and electrolyte imbalances should be corrected. Essential vitamins and minerals also should be provided as needed.
  • Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.
  • Care should be exercised to insure that the needle (or catheter) is well within the lumen of the vein and that extravasation does not occur.
  • Concentrated dextrose solutions should not be administered subcutaneously or intramuscularly.
  • Do not administer unless solution is clear and container is undamaged. Discard unused portion.

Adverse Reactions

Clinical Trials Experience

  • hyperosmolar syndrome, resulting from excessively rapid administration of concentrated dextrose may cause hypovolemia, dehydration, mental confusion and/or loss of consciousness.
  • Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.
  • If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

Postmarketing Experience

There is limited information regarding Dextrose monohydrate injection (10%) Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Dextrose monohydrate injection (10%) Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): C

  • Animal reproduction studies have not been conducted with dextrose. It is also not known whether dextrose can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Dextrose should be given to a pregnant woman only if clearly needed.
  • This product contains no more than 25 mcg/L of aluminum.


Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Dextrose monohydrate injection (10%) in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Dextrose monohydrate injection (10%) during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Dextrose monohydrate injection (10%) in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Dextrose monohydrate injection (10%) in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Dextrose monohydrate injection (10%) in geriatric settings.

Gender

There is no FDA guidance on the use of Dextrose monohydrate injection (10%) with respect to specific gender populations.

Race

There is no FDA guidance on the use of Dextrose monohydrate injection (10%) with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Dextrose monohydrate injection (10%) in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Dextrose monohydrate injection (10%) in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Dextrose monohydrate injection (10%) in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Dextrose monohydrate injection (10%) in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Intravenous

Monitoring

There is limited information regarding Dextrose monohydrate injection (10%) Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Dextrose monohydrate injection (10%) and IV administrations.

Overdosage

  • In the event of overhydration or solute overload during therapy, re-evaluate the patient and institute appropriate corrective measures.

Pharmacology

There is limited information regarding Dextrose monohydrate injection (10%) Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Dextrose monohydrate injection (10%) Mechanism of Action in the drug label.

Structure

  • 10% Dextrose Injection, USP (concentrated dextrose in water) is a sterile, nonpyrogenic, hypertonic solution of Dextrose, USP in water for injection for intravenous administration after appropriate admixture or dilution.
  • 10% Dextrose Injection, USP is provided as a 500 mL volume in a 1000 mL partial-fill container. The container is designed to facilitate admixture or dilution.
  • See table under HOW SUPPLIED for summary of content and characteristics of this concentrated solution.
  • The solution contains no bacteriostat, antimicrobial agent or added buffer and is intended only for use as a single-dose injection following admixture or dilution.
  • The flexible plastic container is fabricated from a specially formulated polyvinyl chloride. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period.
  • Dextrose Injection, USP is a parenteral fluid and nutrient replenisher.
  • Dextrose Injection, USP is chemically designated D-glucose monohydrate (C6H12O6 • H2O), a hexose sugar freely soluble in water. It has the following structural formula:
This image is provided by the National Library of Medicine.

Water for Injection, USP is chemically designated H2O.

Pharmacodynamics

  • When administered intravenously, solutions containing carbohydrate in the form of dextrose restore blood glucose levels and provide calories. Carbohydrate in the form of dextrose may aid in minimizing liver glycogen depletion and exerts a protein sparing action. Dextrose Injection, USP undergoes oxidation to carbon dioxide and water.
  • Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult daily requirement ranges from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production, respectively).
  • Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration of electrolytes in the body compartments, and sodium (Na+) plays a major role in maintaining physiologic equilibrium.

Pharmacokinetics

There is limited information regarding Dextrose monohydrate injection (10%) Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Dextrose monohydrate injection (10%) Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Dextrose monohydrate injection (10%) Clinical Studies in the drug label.

How Supplied

  • 10% Dextrose Injection, USP is supplied in single-dose, partial-fill, flexible containers as follows: a 500 mL volume in a 1000 mL container. See the following table.
This image is provided by the National Library of Medicine.
  • Caloric value calculated on the basis of 3.4 kcal/g of dextrose, hydrous.
This image is provided by the National Library of Medicine.

Revised: June, 2010


Printed in USA EN-2535

Hospira, Inc., Lake Forest, IL 60045 USA

Storage

  • Store at 20 to 25°C (68 to 77°F).
  • Protect from freezing.

Images

Drug Images

Package and Label Display Panel

This image is provided by the National Library of Medicine.

Patient Counseling Information

There is limited information regarding Dextrose monohydrate injection (10%) Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Dextrose monohydrate injection (10%) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

  • DEXTROSE

Look-Alike Drug Names

There is limited information regarding Dextrose monohydrate injection (10%) Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.